AACR Cancer Progress Report 2012

Cantley, Lewis C.; Dalton, William S.; DuBois, Raymond N.; Finn, Olivera J.; Futreal, P. Andrew; Golub, Todd R.; Hait, William N.; Lozano, Guillermina; Maris, John M.; Nelson, William G.; Sawyers, Charles L.; Schreiber, Stuart L.; Spitz, Margaret R.; Steeg, Patricia S.

doi:10.1158/1078-0432.ccr-12-2891

Cited by 27 publications

(13 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large number of oncogenic viruses have been reported in terrestrial and aquatic wildlife and domestic animals 14,15 . Meanwhile, in humans, the number of cancer incidences identified as attributable to pathogens has tripled in only 4 years 16,17 , now accounting for 15% of all human cancers. Furthermore, emerging infectious disease events in humans are dominated by zoonoses (diseases transmitted to humans from animals, 60.3%), with the majority of these (71.8%) originating in wildlife 18–20 .…”

Section: Introductionmentioning

confidence: 99%

Sea turtle fibropapilloma tumors share genomic drivers and therapeutic vulnerabilities with human cancers

et al. 2018

View full text Add to dashboard Cite

Wildlife populations are under intense anthropogenic pressures, with the geographic range of many species shrinking, dramatic reductions in population numbers and undisturbed habitats, and biodiversity loss. It is postulated that we are in the midst of a sixth (Anthropocene) mass extinction event, the first to be induced by human activity. Further, threatening vulnerable species is the increased rate of emerging diseases, another consequence of anthropogenic activities. Innovative approaches are required to help maintain healthy populations until the chronic underlying causes of these issues can be addressed. Fibropapillomatosis in sea turtles is one such wildlife disease. Here, we applied precision-medicine-based approaches to profile fibropapillomatosis tumors to better understand their biology, identify novel therapeutics, and gain insights into viral and environmental triggers for fibropapillomatosis. We show that fibropapillomatosis tumors share genetic vulnerabilities with human cancer types, revealing that they are amenable to treatment with human anti-cancer therapeutics.

show abstract

Section: Introductionmentioning

confidence: 99%

Sea turtle fibropapilloma tumors share genomic drivers and therapeutic vulnerabilities with human cancers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In fact, the use of mathematical modeling has been identified as essential to progress in cancer (42). …”

Section: Discussionmentioning

confidence: 99%

Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow

McGuire¹,

Enderling

Wallace

et al. 2013

Cancer Research

View full text Add to dashboard Cite

Although many clinicians and researchers work to understand cancer, there has been limited success to effectively combine forces and collaborate over time, distance, data and budget constraints. Here we present a workflow template for multidisciplinary cancer therapy that was developed during the 2nd Annual Workshop on Cancer Systems Biology sponsored by Tufts University, Boston, MA in July 2012. The template was applied to the development of a metronomic therapy backbone for neuroblastoma. Three primary groups were identified: clinicians, biologists, and scientists (mathematicians, computer scientists, physicists and engineers). The workflow described their integrative interactions; parallel or sequential processes; data sources and computational tools at different stages as well as the iterative nature of therapeutic development from clinical observations to in vitro, in vivo, and clinical trials. We found that theoreticians in dialog with experimentalists could develop calibrated and parameterized predictive models that inform and formalize sets of testable hypotheses, thus speeding up discovery and validation while reducing laboratory resources and costs. The developed template outlines an interdisciplinary collaboration workflow designed to systematically investigate the mechanistic underpinnings of a new therapy and validate that therapy to advance development and clinical acceptance.

show abstract

“…There are numerous additional cancer risk factors, including reproductive factors, occupational cancer-causing agents, and environmental pollutants (84) (see Figure 8, p. 34). Given that it can be difficult for people to avoid or reduce their exposure to many of these factors, it is imperative that policies are put in place to ensure that everyone lives in a safe and healthy environment.…”

Section: Preventing Cancer From Developingmentioning

confidence: 99%

“…The first of these molecularly targeted therapeutics, vismodegib (Erivedge), was approved by the FDA for the treatment of locally advanced or metastatic basal cell carcinoma in January 2012 (84). …”

Section: Transforming Lives Through Precision Medicinementioning

confidence: 99%